- Home
- RPRX vs HRL Comparison
RPRX vs HRL Comparison
Compare RPRX & HRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- HRL
- Stock Information
- Founded
- RPRX 1996
- HRL 1891
- Country
- RPRX United States
- HRL United States
- Employees
- RPRX N/A
- HRL N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- HRL Meat/Poultry/Fish
- Sector
- RPRX Health Care
- HRL Consumer Staples
- Exchange
- RPRX Nasdaq
- HRL Nasdaq
- Market Cap
- RPRX 13.9B
- HRL 16.6B
- IPO Year
- RPRX 2020
- HRL N/A
- Fundamental
- Price
- RPRX $35.59
- HRL $29.13
- Analyst Decision
- RPRX Strong Buy
- HRL Buy
- Analyst Count
- RPRX 3
- HRL 3
- Target Price
- RPRX $48.33
- HRL $34.00
- AVG Volume (30 Days)
- RPRX 3.5M
- HRL 3.8M
- Earning Date
- RPRX 08-06-2025
- HRL 09-03-2025
- Dividend Yield
- RPRX 2.48%
- HRL 3.99%
- EPS Growth
- RPRX 37.60
- HRL N/A
- EPS
- RPRX 2.45
- HRL 1.36
- Revenue
- RPRX $2,263,845,000.00
- HRL $11,924,157,000.00
- Revenue This Year
- RPRX $29.35
- HRL $2.67
- Revenue Next Year
- RPRX $7.58
- HRL $2.57
- P/E Ratio
- RPRX $14.47
- HRL $21.38
- Revenue Growth
- RPRX 1.13
- HRL N/A
- 52 Week Low
- RPRX $24.05
- HRL $27.59
- 52 Week High
- RPRX $36.89
- HRL $33.80
- Technical
- Relative Strength Index (RSI)
- RPRX 52.61
- HRL 39.20
- Support Level
- RPRX $35.24
- HRL $29.20
- Resistance Level
- RPRX $36.89
- HRL $30.09
- Average True Range (ATR)
- RPRX 0.62
- HRL 0.74
- MACD
- RPRX -0.14
- HRL -0.18
- Stochastic Oscillator
- RPRX 22.16
- HRL 2.50
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About HRL Hormel Foods Corporation
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and become a branded food company. The firm sells its wares through multiple channels, including US retail (62% of fiscal 2024 sales), US food service (32%), and international (6%). By product, 72% of fiscal 2024 sales were from perishable food and 28% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.